Essity Reports Mixed Q2 2026: Sales Up but Profitability Pressured by Cost Inflation
Event summary
- Net sales increased 2.6% to SEK 35,061m, driven by volume growth (1.4%) offset by price/mix decline (-1.1%).
- EBITA margin excluding IAC dropped 0.3 percentage points to 13.4%, with Consumer Tissue margins hit hardest.
- New share buyback program for SEK 3bn commenced May 12, 2026.
- AI-driven procurement solution deployed to improve efficiency and data quality.
- Strategic review of Consumer Tissue business underway amid portfolio optimization efforts.
The big picture
Essity's Q2 results reflect broader challenges in the consumer goods sector, where geopolitical volatility and cost inflation are testing margins. The company's focus on innovation and portfolio optimization aligns with industry trends toward operational agility and selective growth investments. With SEK 35bn in net sales, Essity's ability to navigate these pressures will signal its resilience amid shifting market dynamics.
What we're watching
- Cost Inflation Management
- Whether Essity can offset higher input and transportation costs through price increases, particularly in Consumer Tissue.
- Portfolio Optimization
- The pace at which strategic reviews of underperforming segments like Consumer Tissue yield tangible improvements.
- AI Integration
- How effectively Essity scales AI-driven solutions across its value chain to sustain efficiency gains.
Related topics